Non-myeloablative Hematopoietic Cell Transplantation (Mini-Allograft / Reduced Intensity Conditioning Transplant) (CPB 0634, reviewed 2026-02-25)
Summary
Aetna considers non-myeloablative hematopoietic cell transplantation (mini-allograft) medically necessary for acute lymphoblastic leukemia, acute myelogenous leukemia, aplastic anemia including paroxysmal nocturnal hemoglobinuria, chronic lymphocytic leukemia, chronic myelogenous leukemia, Hodgkin's disease, multiple myeloma, myelofibrosis, myelodysplasia, neuroblastoma, non-Hodgkin's lymphoma, sickle cell anemia and thalassemia major, for diseases where conventional allogeneic hematopoietic cell transplantation is an established alternative. Aetna considers it experimental, investigational or unproven for acquired angioedema, autoimmune diseases, breast cancer, essential thrombocythemia and polycythemia vera, melanoma, ovarian cancer, renal cancer and testicular cancer. For patients eligible for conventional ASCT, mini-allograft is a technical variation of an established procedure, while for patients who are ineligible for conventional ASCT it is still considered an investigational procedure.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.